125 related articles for article (PubMed ID: 26219913)
1. Suppression of Cytosolic NADPH Pool by Thionicotinamide Increases Oxidative Stress and Synergizes with Chemotherapy.
Tedeschi PM; Lin H; Gounder M; Kerrigan JE; Abali EE; Scotto K; Bertino JR
Mol Pharmacol; 2015 Oct; 88(4):720-7. PubMed ID: 26219913
[TBL] [Abstract][Full Text] [Related]
2. NAD kinase regulates the size of the NADPH pool and insulin secretion in pancreatic β-cells.
Gray JP; Alavian KN; Jonas EA; Heart EA
Am J Physiol Endocrinol Metab; 2012 Jul; 303(2):E191-9. PubMed ID: 22550069
[TBL] [Abstract][Full Text] [Related]
3. NAD+ Kinase as a Therapeutic Target in Cancer.
Tedeschi PM; Bansal N; Kerrigan JE; Abali EE; Scotto KW; Bertino JR
Clin Cancer Res; 2016 Nov; 22(21):5189-5195. PubMed ID: 27582489
[TBL] [Abstract][Full Text] [Related]
4. Butyric acid-induced rat jugular blood cytosolic oxidative stress is associated with SIRT1 decrease.
Cueno ME; Imai K; Tamura M; Ochiai K
Cell Stress Chaperones; 2014 Mar; 19(2):295-8. PubMed ID: 24052229
[TBL] [Abstract][Full Text] [Related]
5. Evidence that feedback inhibition of NAD kinase controls responses to oxidative stress.
Grose JH; Joss L; Velick SF; Roth JR
Proc Natl Acad Sci U S A; 2006 May; 103(20):7601-6. PubMed ID: 16682646
[TBL] [Abstract][Full Text] [Related]
6. NAD kinase levels control the NADPH concentration in human cells.
Pollak N; Niere M; Ziegler M
J Biol Chem; 2007 Nov; 282(46):33562-33571. PubMed ID: 17855339
[TBL] [Abstract][Full Text] [Related]
7. Synergistic cooperation between ABT-263 and MEK1/2 inhibitor: effect on apoptosis and proliferation of acute myeloid leukemia cells.
Airiau K; Prouzet-Mauléon V; Rousseau B; Pigneux A; Jeanneteau M; Giraudon M; Allou K; Dubus P; Belloc F; Mahon FX
Oncotarget; 2016 Jan; 7(1):845-59. PubMed ID: 26625317
[TBL] [Abstract][Full Text] [Related]
8. The Combination of Sorafenib and Everolimus Abrogates mTORC1 and mTORC2 upregulation in osteosarcoma preclinical models.
Pignochino Y; Dell'Aglio C; Basiricò M; Capozzi F; Soster M; Marchiò S; Bruno S; Gammaitoni L; Sangiolo D; Torchiaro E; D'Ambrosio L; Fagioli F; Ferrari S; Alberghini M; Picci P; Aglietta M; Grignani G
Clin Cancer Res; 2013 Apr; 19(8):2117-31. PubMed ID: 23434734
[TBL] [Abstract][Full Text] [Related]
9. Perifosine and sorafenib combination induces mitochondrial cell death and antitumor effects in NOD/SCID mice with Hodgkin lymphoma cell line xenografts.
Locatelli SL; Giacomini A; Guidetti A; Cleris L; Mortarini R; Anichini A; Gianni AM; Carlo-Stella C
Leukemia; 2013 Aug; 27(8):1677-87. PubMed ID: 23360848
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of NADPH oxidase 1 activity and blocking the binding of cytosolic and membrane-bound proteins by honokiol inhibit migratory potential of melanoma cells.
Prasad R; Kappes JC; Katiyar SK
Oncotarget; 2016 Feb; 7(7):7899-912. PubMed ID: 26760964
[TBL] [Abstract][Full Text] [Related]
11. NADK-mediated de novo NADP(H) synthesis is a metabolic adaptation essential for breast cancer metastasis.
Ilter D; Drapela S; Schild T; Ward NP; Adhikari E; Low V; Asara J; Oskarsson T; Lau EK; DeNicola GM; McReynolds MR; Gomes AP
Redox Biol; 2023 May; 61():102627. PubMed ID: 36841051
[TBL] [Abstract][Full Text] [Related]
12. Sorafenib increases efficacy of vorinostat against human hepatocellular carcinoma through transduction inhibition of vorinostat-induced ERK/NF-κB signaling.
Hsu FT; Liu YC; Chiang IT; Liu RS; Wang HE; Lin WJ; Hwang JJ
Int J Oncol; 2014 Jul; 45(1):177-88. PubMed ID: 24807012
[TBL] [Abstract][Full Text] [Related]
13. Design and discovery of novel quinazolinedione-based redox modulators as therapies for pancreatic cancer.
Pathania D; Sechi M; Palomba M; Sanna V; Berrettini F; Sias A; Taheri L; Neamati N
Biochim Biophys Acta; 2014 Jan; 1840(1):332-43. PubMed ID: 23954204
[TBL] [Abstract][Full Text] [Related]
14. Sorafenib enhances the chemotherapeutic efficacy of S-1 against hepatocellular carcinoma through downregulation of transcription factor E2F-1.
Zhai JM; Yin XY; Lai YR; Hou X; Cai JP; Hao XY; Liang LJ; Zhang LJ
Cancer Chemother Pharmacol; 2013 May; 71(5):1255-64. PubMed ID: 23435877
[TBL] [Abstract][Full Text] [Related]
15. NADPH oxidases as therapeutic targets in chronic myelogenous leukemia.
Sánchez-Sánchez B; Gutiérrez-Herrero S; López-Ruano G; Prieto-Bermejo R; Romo-González M; Llanillo M; Pandiella A; Guerrero C; Miguel JF; Sánchez-Guijo F; Del Cañizo C; Hernández-Hernández A
Clin Cancer Res; 2014 Aug; 20(15):4014-25. PubMed ID: 24833663
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic strategies by modulating oxygen stress in cancer and inflammation.
Fang J; Seki T; Maeda H
Adv Drug Deliv Rev; 2009 Apr; 61(4):290-302. PubMed ID: 19249331
[TBL] [Abstract][Full Text] [Related]
17. MNADK, a Long-Awaited Human Mitochondrion-Localized NAD Kinase.
Zhang R
J Cell Physiol; 2015 Aug; 230(8):1697-701. PubMed ID: 25641397
[TBL] [Abstract][Full Text] [Related]
18. Dual pH-sensitive oxidative stress generating micellar nanoparticles as a novel anticancer therapeutic agent.
Park S; Kwon B; Yang W; Han E; Yoo W; Kwon BM; Lee D
J Control Release; 2014 Dec; 196():19-27. PubMed ID: 25278257
[TBL] [Abstract][Full Text] [Related]
19. Idh1 protects murine hepatocytes from endotoxin-induced oxidative stress by regulating the intracellular NADP(+)/NADPH ratio.
Itsumi M; Inoue S; Elia AJ; Murakami K; Sasaki M; Lind EF; Brenner D; Harris IS; Chio II; Afzal S; Cairns RA; Cescon DW; Elford AR; Ye J; Lang PA; Li WY; Wakeham A; Duncan GS; Haight J; You-Ten A; Snow B; Yamamoto K; Ohashi PS; Mak TW
Cell Death Differ; 2015 Nov; 22(11):1837-45. PubMed ID: 25882048
[TBL] [Abstract][Full Text] [Related]
20. Metformin increases antitumor activity of MEK inhibitors through GLI1 downregulation in LKB1 positive human NSCLC cancer cells.
Della Corte CM; Ciaramella V; Di Mauro C; Castellone MD; Papaccio F; Fasano M; Sasso FC; Martinelli E; Troiani T; De Vita F; Orditura M; Bianco R; Ciardiello F; Morgillo F
Oncotarget; 2016 Jan; 7(4):4265-78. PubMed ID: 26673006
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
